NeoGenomics
Receive regular headline summaries whenever high-quality news is generated for NeoGenomics. We'll never share your email address with others.
Selected Headlines
| Date | Headline (link) | Source | Relevant Snippet |
|---|---|---|---|
| 1/23/2022 | Bridgefront Capital LLC Acquires New Position in NeoGenomics, Inc. (NASDAQ:NEO) | com-unik.info | Bridgefront Capital LLC purchased a new position in shares of NeoGenomics, Inc. (NASDAQ:NEO) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 4,677 shares of the medical research company’s stock, valued at approximately $226,000.A number of other institutional investors and hedge funds also recently bought and sold shares of NEO. Harbor Investment Advisory LLC bought a new position in ... |
| 1/23/2022 | NeoGenomics, Inc. (NASDAQ:NEO) Given Average Recommendation of “Buy” by Analysts | com-unik.info | Shares of NeoGenomics , Inc. (NASDAQ:NEO) have earned an average recommendation of “Buy” from the eleven ratings firms that are presently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $51.40.A number of analysts ... |
| 1/23/2022 | Bridgefront Capital LLC Acquires Shares of 4,677 NeoGenomics, Inc. (NASDAQ:NEO) | thelincolnianonline.com | Bridgefront Capital LLC acquired a new stake in shares of NeoGenomics, Inc. (NASDAQ:NEO) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,677 shares of the medical research company’s stock, valued at approximately $226,000.A number of other hedge funds also recently modified their holdings of the business. Harbor Investment Advisory LLC bought a new ... |
| 1/22/2022 | O Shaughnessy Asset Management LLC Purchases 1,657 Shares of NeoGenomics, Inc. (NASDAQ:NEO) | rivertonroll.com | O Shaughnessy Asset Management LLC increased its position in NeoGenomics, Inc. (NASDAQ:NEO) by 29.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,288 shares of the medical research company’s stock after purchasing an additional 1,657 shares during the period. O Shaughnessy Asset Management LLC’s holdings in NeoGenomics were worth $352,000 at ... |
| 1/22/2022 | O Shaughnessy Asset Management LLC Increases Stake in NeoGenomics, Inc. (NASDAQ:NEO) | thelincolnianonline.com | O Shaughnessy Asset Management LLC boosted its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 29.4% in the 3rd quarter, Holdings Channel reports. The fund owned 7,288 shares of the medical research company’s stock after buying an additional 1,657 shares during the period. O Shaughnessy Asset Management LLC’s holdings in NeoGenomics were worth $352,000 as of its most recent filing with the Securities and Exchange Commission.Other ... |
| 1/22/2022 | O Shaughnessy Asset Management LLC Grows Holdings in NeoGenomics, Inc. (NASDAQ:NEO) | etfdailynews.com | O Shaughnessy Asset Management LLC increased its position in NeoGenomics, Inc. (NASDAQ:NEO) by 29.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,288 shares of the medical research company’s stock after acquiring an additional 1,657 shares during the quarter. O Shaughnessy Asset Management LLC’s holdings in NeoGenomics were worth $352,000 at the end of ... |
| 1/22/2022 | NeoGenomics, Inc. (NASDAQ:NEO) Shares Acquired by O Shaughnessy Asset Management LLC | etfdailynews.com | O Shaughnessy Asset Management LLC grew its holdings in NeoGenomics , Inc. (NASDAQ:NEO) by 29.4% in the 3rd quarter, Holdings Channel.com reports. The fund owned 7,288 shares of the medical research company’s stock after buying an additional 1,657 shares during the period. O Shaughnessy Asset Management LLC’s holdings in NeoGenomics were worth $352,000 as of its most recent SEC filing.A number of other hedge funds and other ... |
| 1/22/2022 | NeoGenomics, Inc. (NASDAQ:NEO) Shares Purchased by Barclays PLC | The Markets Daily | Barclays PLC boosted its holdings in shares of NeoGenomics , Inc. (NASDAQ:NEO) by 11.0% in the third quarter, HoldingsChannel.com reports. The fund owned 137,913 shares of the medical research company’s stock after buying an additional 13,691 shares during the quarter. Barclays PLC’s holdings in NeoGenomics were worth $6,652,000 at the end of the most recent reporting period.A number of other institutional investors and hedge funds have also ... |
| 1/22/2022 | Barclays PLC Increases Holdings in NeoGenomics, Inc. (NASDAQ:NEO) | baseballnewssource.com | Barclays PLC increased its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 11.0% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 137,913 shares of the medical research company’s stock after purchasing an additional 13,691 shares during the quarter. Barclays PLC owned about 0.11% of NeoGenomics worth $6,652,000 at the end of the most recent quarter.Several other hedge ... |
| 1/22/2022 | Bank Julius Baer & Co. Ltd Zurich Takes Position in NeoGenomics, Inc. (NASDAQ:NEO) - Dakota Financial News | Dakota Financial News | Bank Julius Baer & Co. Ltd Zurich acquired a new position in NeoGenomics, Inc. (NASDAQ:NEO) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 328,733 shares of the medical research company’s stock, valued at approximately $15,858,000. Bank Julius Baer & Co. Ltd Zurich owned about 0.27% of NeoGenomics at the end of the most recent quarter.A number of ... |
| 1/22/2022 | NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Bellevue Group AG | theenterpriseleader.com | Bellevue Group AG trimmed its position in shares of NeoGenomics , Inc. (NASDAQ:NEO) by 31.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 561,683 shares of the medical research company’s stock after selling 256,630 shares during the period. Bellevue Group AG owned approximately 0.46% of NeoGenomics worth $27,096,000 at the end of the ... |
| 1/21/2022 | NeoGenomics (NASDAQ:NEO) Sets New 12-Month Low at $23.15 - Stock Observer | thestockobserver.com | ... and last traded at $23.55, with a volume of 3531 shares changing hands. The stock had previously closed at $23.40.Several research firms have issued reports on NEO. Zacks Investment Research raised shares of NeoGenomics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 12th. Morgan Stanley lowered shares of NeoGenomics from an “overweight” rating to an “equal weight” rating ... |
| 1/21/2022 | NeoGenomics (NASDAQ:NEO) Sets New 52-Week Low at $23.15 | The Markets Daily | ... 23.15 and last traded at $23.55, with a volume of 3531 shares trading hands. The stock had previously closed at $23.40.Several research firms have recently commented on NEO. Raymond James raised shares of NeoGenomics from a “market perform” rating to an “outperform” rating and set a $53.00 price objective for the company in a research note on Thursday, October 14th. Zacks Investment Research raised shares of NeoGenomics ... |
| 1/21/2022 | -$0.13 EPS Expected for NeoGenomics, Inc. (NASDAQ:NEO) This Quarter - Slater Sentinel | slatersentinel.com | Equities research analysts expect NeoGenomics, Inc. (NASDAQ:NEO) to report ($0.13) earnings per share (EPS) for the current quarter, Zacks reports. Four analysts have made estimates for NeoGenomics’ earnings, with the highest EPS estimate coming in at ($0.10) and the lowest estimate coming in at ($0.17). NeoGenomics reported earnings per share of $0.14 during the same quarter last year, which would indicate a negative year-over-year growth rate ... |
| 1/21/2022 | Glenview Trust Co Decreases Stake in NeoGenomics, Inc. (NASDAQ:NEO) | com-unik.info | Glenview Trust Co lowered its position in NeoGenomics, Inc. (NASDAQ:NEO) by 15.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,851 shares of the medical research company’s stock after selling 2,155 shares during the quarter. Glenview Trust Co’s holdings in NeoGenomics were worth $572,000 as of its most recent SEC filing.A number of other ... |
| 1/21/2022 | NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Glenview Trust Co | thelincolnianonline.com | Glenview Trust Co lowered its stake in shares of NeoGenomics , Inc. (NASDAQ:NEO) by 15.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,851 shares of the medical research company’s stock after selling 2,155 shares during the quarter. Glenview Trust Co’s holdings in NeoGenomics were worth $572,000 at the end of the most recent reporting period ... |
| 1/20/2022 | $127.76 Million in Sales Expected for NeoGenomics, Inc. (NASDAQ:NEO) This Quarter | Daily Political | Analysts expect that NeoGenomics, Inc. (NASDAQ:NEO) will report $127.76 million in sales for the current quarter, according to Zacks Investment Research . Four analysts have provided estimates for NeoGenomics’ earnings, with the highest sales estimate coming in at $135.00 million and the lowest estimate coming in at $124.49 million. NeoGenomics reported sales of $126.00 million in the same quarter last year, which indicates a positive year over year growth ... |
| 1/20/2022 | NeoGenomics – Consensus Indicates Potential -11.3% Downside | directorstalkinterviews.com | ... for the purpose of diagnosis; and testing services in support of its pharmaceutical clients’ oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics has a strategic collaboration with Inivata Limited for the commercialization of its InVisionFirst-Lung liquid biopsy test in the United States. NeoGenomics was founded in 2001 and is headquartered in Fort Myers, Florida.This article ... |
| 1/20/2022 | Public Sector Pension Investment Board Has $11.97 Million Position in NeoGenomics, Inc. (NASDAQ:NEO) | thelincolnianonline.com | Public Sector Pension Investment Board raised its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 3.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 248,164 shares of the medical research company’s stock after acquiring an additional 7,190 shares during the period. Public Sector Pension Investment Board owned about 0.20% of NeoGenomics worth ... |
| 1/19/2022 | Global Human Gene Sequencing Markets, Strategies & Trends Report 2022-2025: Sequencing Adoption and Cannibalization, Genetic Counselling as an Industry, Sequencing as a Commodity | Globe Newswire | ... What are the issues? Find the opportunities, and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.Human Gene Sequencing Recent DevelopmentsMyriad Genetics Projects Return to Profitability NeoGenomics to Acquire Inivata OncoDNA, Institut Curie Partner on Liquid Biopsy Research Cancer Heritability Gene Set Expanded Whole-Genome Sequencing Could Replace Cytogenetics Twist Bioscience, Berry Genomics Partner on Targeted NGS Assays Ancestry Shutters Health Offering ... |